Clinical and Molecular Prognostic Nomograms for Patients with Papillary Renal Cell Carcinoma

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 18

PMID 39692801

Authors

Xuhui Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To summarize the clinicopathological characteristics and prognostic factors of papillary renal cell carcinoma (pRCC) and to construct clinical and molecular prognostic nomograms using existing databases.

Methods: Clinical prognostic models were developed using the Surveillance, Epidemiology, and End Results (SEER) database, while molecular prognostic models were constructed using The Cancer Genome Atlas (TCGA) database. Cox regression and LASSO regression were employed to identify clinicopathological features and molecular markers related to prognosis. The accuracy of the prognostic models was assessed using ROC curves, C-index, decision curve analysis (DCA) curves, and calibration plots.

Results: In the 2004-2015 SEER cohort, Cox regression analysis revealed that age, grade, AJCC stage, N stage, M stage, and surgery were independent predictors of overall survival (OS) and cancer-specific survival (CSS) in pRCC patients. ROC curves, C-index, and DCA curves indicated that the prognostic nomogram based on clinical independent predictors had better predictive ability than TNM staging and SEER staging. Additionally, in the TCGA cohort, M stage, clinical stage, and the molecular markers IDO1 and PLK1 were identified as independent risk factors. The prognostic nomogram based on molecular independent risk factors effectively predicted the 3-year and 5-year OS and CSS for pRCC patients.

Conclusions: The clinical and molecular nomograms constructed in this study provide robust predictive tools for individualized prognosis in pRCC patients, offering better accuracy than traditional staging systems.

References

Le X, Wang X, Zhao H, Chen R, Ge P . Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma. BMC Urol. 2020; 20(1):148. PMC: 7493181. DOI: 10.1186/s12894-020-00716-0. View

Sukov W, Lohse C, Leibovich B, Thompson R, Cheville J . Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol. 2011; 187(1):54-9. DOI: 10.1016/j.juro.2011.09.053. View

Delahunt B, Eble J . Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997; 10(6):537-44. View

Haake S, Weyandt J, Rathmell W . Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res. 2016; 14(7):589-98. PMC: 4955752. DOI: 10.1158/1541-7786.MCR-16-0115. View

Strebhardt K . Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010; 9(8):643-60. DOI: 10.1038/nrd3184. View

Margulis V, Tamboli P, Matin S, Swanson D, Wood C . Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008; 112(7):1480-8. DOI: 10.1002/cncr.23322. View

Trpkov K, Hes O, Williamson S, Adeniran A, Agaimy A, Alaghehbandan R . New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021; 34(7):1392-1424. DOI: 10.1038/s41379-021-00779-w. View

Beck S, Patel M, Snyder M, Kattan M, Motzer R, Reuter V . Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2003; 11(1):71-7. DOI: 10.1007/BF02524349. View

Patard J, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A . Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005; 23(12):2763-71. DOI: 10.1200/JCO.2005.07.055. View

10.

Pan H, Ye L, Zhu Q, Yang Z, Hu M . The effect of the papillary renal cell carcinoma subtype on oncological outcomes. Sci Rep. 2020; 10(1):21073. PMC: 7713298. DOI: 10.1038/s41598-020-78174-9. View

11.

Steffens S, Janssen M, Roos F, Becker F, Schumacher S, Seidel C . Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Eur J Cancer. 2012; 48(15):2347-52. DOI: 10.1016/j.ejca.2012.05.002. View

12.

Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q . ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021; 20(1):142. PMC: 8570002. DOI: 10.1186/s12943-021-01443-2. View

13.

Trpkov K, Hes O . New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology. 2018; 74(1):31-59. DOI: 10.1111/his.13727. View

14.

Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A . Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun. 2015; 6:6336. PMC: 4383019. DOI: 10.1038/ncomms7336. View

15.

Gettman M, Blute M, Spotts B, Bryant S, Zincke H . Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer. 2001; 91(2):354-61. DOI: 10.1002/1097-0142(20010115)91:2<354::aid-cncr1009>3.0.co;2-9. View

16.

Kim S, Kwon S, Yoon J, Ahn S . The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells. Int J Oncol. 2010; 36(4):867-72. DOI: 10.3892/ijo_00000564. View

17.

Linehan W, Spellman P, Ricketts C, Creighton C, Fei S, Davis C . Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2015; 374(2):135-45. PMC: 4775252. DOI: 10.1056/NEJMoa1505917. View

18.

Malouf G, Su X, Zhang J, Creighton C, Ho T, Lu Y . DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016; 22(24):6236-6246. PMC: 5135666. DOI: 10.1158/1078-0432.CCR-15-1217. View

19.

Courthod G, Tucci M, Di Maio M, Scagliotti G . Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015; 96(1):100-12. DOI: 10.1016/j.critrevonc.2015.05.008. View

20.

Fernandes D, Lopes J . Pathology, therapy and prognosis of papillary renal carcinoma. Future Oncol. 2015; 11(1):121-32. DOI: 10.2217/fon.14.133. View